Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study

Journal of the American Academy of Nurse Practitioners

Volumn 21, Issue 3, 2009, Pages 140-148

  Jurado, Jeronimo ^a   Ybarra, Juan ^b,c   Solanas, Pascual ^a   Caula, Jacint ^a   Gich, Ignasi ^d   Pou, Jose M ^b,d   Romeo, June Hart ^e  

^a Primary Care   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c CENTRO MÉDICO TEKNON   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Southwest Rheumatology and Research Group   (United States)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Metabolic syndrome; Prevalence; Risk factors; Type 2

Indexed keywords

CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CROSS-SECTIONAL STUDY; FEMALE; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION; PREVALENCE; RISK FACTOR; SEX RATIO; SPAIN; TOBACCO DEPENDENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POPULATION; PREVALENCE; RISK FACTORS; SEX DISTRIBUTION; SPAIN; TOBACCO USE DISORDER;

EID: 62349092599     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2008.00377.x     Document Type: Article

References (60)

1. ACCORD Study Group 2004). The ACCORD trial: A multidisciplinary approach to control cardiovascular risk in type 2 diabetes mellitus. Practical Diabetol, 23, 6 11.
2. Adler, A. I., Stratton, I. M., Neil, H. A., Yudkin, J. S., Matthews, D. R., Cull, C. A., et al 2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ, 321, 412 419.
3. American Diabetes Association 2004a). Aspirin therapy in diabetes (Position Statement). Diabetes Care, 27 (Suppl. 1 S72 S73.
4. American Diabetes Association 2004b). Dyslipidemia management in adults with diabetes. Diabetes Care, 27 (Suppl. 1 S68 S71.
5. American Diabetes Association 2004c). Standards of medical care in diabetes. Diabetes Care, 27, S15 S35.
6. Beckman, J. A., Creager, M. A. Libby, P 2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. Journal of the American Medical Association, 287, 2570 2581.
7. Bhatt, D. L., Marso, S. P., Hirsch, A. T., Ringleb, P. A., Hacke, W. Topol, E. J 2002). Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. American Journal of Cardiology, 90, 625 628.
8. Brunner, E. J., Shipley, M. J., Witte, D. R., Fuller, J. H. Marmot, M. G 2006). Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care, 29, 26 31.
9. Daviglus, M. L., Lloyd-Jones, D. M. Pirzada, A 2006). Preventing cardiovascular disease in the 21st century: Therapeutic and preventive implications of current evidence. American Journal of Cardiovascular Drugs, 6, 87 101.
10. De la Calle, H., Costa, A., Díez-Espino, J., Franch, J. Goday, A 2003). Evaluation on the compliance of the metabolic control aims in outpatients with type 2 diabetes mellitus in Spain. The TranSTAR study. Medicina Clinica (Barc), 120, 446 450.
11. Del Canizo-Gomez, F. J. Moreira-Andres, M. N 2004). Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Research and Clinical Practice, 65, 125 133.
12. Engström, G., Stavenow, L., Hedblad, B., Lind, P., Eriksson, K. F., Janzon, L., et al 2003). Inflammation-sensitive plasma proteins, diabetes and mortality and incidence of myocardial infarction and stroke. Diabetes, 53, 442 447.
13. Esmatjes, E., Castell, C., Franch, J., Puigorial, E. Hernaez, R 2004). Acetylsalicylic acid consumption in patients with diabetes mellitus. Medicina Clinica (Barc), 122, 96 98.
14. Estacio, R. O., Jeffers, B. W., Gifford, N. Schrier, R. W 2000). Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care, 23 (Suppl. 2 B54 B64.
15. European Diabetes Policy Group 1998 1999). A desktop guide to type 2 diabetes mellitus. Diabetic Medicine, 16, 16 30.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001). Executive summary of the third report of the National Cholesterol Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486 2497.
17. Fox, C. S., Coady, S., Sorlie, P. D., Levy, D., Meigs, J. B., D'Agostino, R. B., Sr., et al 2004). Trends in cardiovascular complications of diabetes. Journal of the American Medical Association, 292, 2495 2499.
18. Garcia, O., Lozano, J. V., Vegazo, O., Jimenez, F. J., Llisterri, J. L. Redón, J 2003). Control of blood pressure in diabetic patients in primary care setting. DIAPA study. Medicina Clinica, 120, 529 536.
19. Gerstein, H. C., Malmberg, K., Capes, S. Yusuf, S 2001). Cardiovascular diseases. In H. C. Gerstein R. B Haynes (Eds Evidence-based diabetes care (pp. 488 514). Hamilton, Ontario : BC Decker.
20. Gerstein, H. C., Mann, J. F. Yi, Q 2001). Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. Journal of the American Medical Association, 286, 421 426.
21. Grundy, S. M 2007). Related articles, links metabolic syndrome: A multiplex cardiovascular risk factor. Journal of Clinical Endocrinology and Metabolism, 92, 399 404.
22. Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., et al 1999). Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Hearth Association. Circulation, 100, 1134 1146.
23. Gu, K., Cowie, C. C. Harris, M. I 1999). Diabetes and decline in heart disease mortality in US adults. Journal of the American Medical Association, 281, 1291 1297.
24. Haffner, S. M., Lehto, S., Rönemaa, T., Pyörälä, K. Laakso, M 1998). Mortality from coronary heart disease in subjects with type 2 diabetes and non diabetic subjects with and without prior myocardial infarction. New England Journal of Medicine, 339, 229 234.
25. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D., Julius, S., et al 1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351, 1755 1762.
26. Hayden, M., Pignone, M. Phillips, C 2002). Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 136, 161 171.
27. Hurst, I. R. Lee, R. W 2003). Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: Mechanisms and management. Annals of Internal Medicine, 139, 824 834.
28. Huxley, R., Barzi, F. Woodward, M 2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ, 332, 73 78.
29. Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M., et al 2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683 689.
30. Jönson, B 2002). Revealing the cost of Type II diabetes in Europe. Diabetologia, 45, S5 S12.
31. Jurado, J., Bataller, F., Dorca, A., García, F., Brossa, N., Barnera, T., et al 2004). Diabetic foot risk factors in diabetic patients with and without polyneuropathy (The North Catalonia Diabetes Study) [Abstract]. Diabetologia, 47 (Suppl. 1 A373 A374.
32. Kahn, R., Buse, J., Ferrannini, E. Stern, M 2005). The metabolic syndrome: Time for a critical appraisal Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 48, 1684 1699.
33. Lawlor, D. A., Fraser, A., Ebrahim, S. Smith, G. D 2007). Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Medicine, 4 (8 e263.
34. Lee, J., Ma, S., Heng, D., Tan, C. E., Chew, S. K., Hughes, K., et al 2007). Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore cardiovascular cohort study. Diabetes Care, 30, 343 347.
35. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. Collins, R. Prospective studies collaboration 2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360, 1903 1913.
36. Marre, M 2007). Reducing cardiovascular risk in diabetes. Journal of Hypertension. Supplement, 25 (Suppl. 1 S19 S22.
37. Masia, R., Sala, J., Rolhfs, I., Piulats, R., Manresa, J. M. Marrugat, J 2004). Prevalence of diabetes mellitus in the province of Girona, Spain: The REGICOR study. Revista Espanola de Cardiologia, 57, 261 264.
38. Massi-Benedetti, M., Jonsson, B., Williams, R., Van Gaal, L., Lucioni, C., Koopmanschap, M., et al 2002). The cost of diabetes in Europe - Type II: The CODE-2 Study. Diabetologia, 45 (Suppl S1 S28.
39. Mazzone, T 2007). Prevention of macrovascular disease in patients with diabetes mellitus: Opportunities for intervention. American Journal of Medicine, 120 (9, Suppl. 2, S26 S32.
40. Meigs, J. B., Nathan, D. M., D'Agostino, R. B., Sr. Wilson, P. W 2002). Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care, 25, 1845 1850.
41. Muntner, P., He, J., Roccella, E. J. Whelton, P. K 2002). The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension, 39, 897 904.
42. Östgren, C. J., Lindblad, U., Melander, A. Råstam, L 2002). Survival in patients with type 2 diabetes in a Swedish Community: Skaraborg hypertension and diabetes project. Diabetes Care, 25, 1297 1302.
43. Renders, C. M., Valk, G. D., de Sonnaville, J. J., Twisk, J., Kriegsman, D. M., Heine, R. J., et al 2003). Quality of care for patients with Type 2 diabetes mellitus - A long-term comparison of two quality improvement programmes in the Netherlands. Diabetic Medicine, 20, 846 852.
44. Report from the American Diabetes Association 2003). Economic cost of diabetes in the U.S. in 2002. Diabetes Care, 26, 917 932.
45. Ross, R 1999). Atherosclerosis - An inflammatory disease. New England Journal of Medicine, 340, 115 126.
46. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., et al 2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ, 321, 405 412.
47. Turner, R. C., Millns, H., Neil, H. A., Stratton, I. M., Manley, S. E., Matthews, D. R., et al 1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ, 316, 823 828.
48. UK Prospective Diabetes Study Group 1998a). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ, 317, 713 720.
49. UK Prospective Diabetes Study Group 1998b). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837 853.
50. UK Prospective Diabetes Study Group 1998c). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ, 317, 703 713.
51. U.S. Preventive Services Task Force 2002). Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Annals of Internal Medicine, 136, 157 160.
52. Valmadrid, C. T., Klein, R., Moss, S. E. Klein, B. E 2000). The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Archives of Internal Medicine, 160, 1093 1100.
53. Vegazo, O., Llisterri, J. L., Jimenez, F. J., Aznar, J., Vicente, J. Estiarte, R 2003). Effectiveness of combined therapy at set doses in a cohort of hypertense patients not controlled by single therapy. Atencion Primaria, 31 (3 163 169.
54. Wakefield, J., Herbert, C. P., Maclure, M., Dormuth, C., Wright, J. M., Legare, J., et al 2003). Commitment to change statements can predict actual change in practice. Journal of Continuing Education in the Health Professions, 23, 81 93.
55. West, M. J., White, H. D., Simes, R. J., Kirby, A., Watson, J. D., Anderson, N. E., et al 2002). Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipidmodifying therapy with pravastatin. Journal of Hypertension, 20, 2513 2517.
56. Wild, S., Roglic, G., Green, A., Sigree, R. King, H 2004). Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care, 5, 1047 1053.
57. Williams, R., Van Gaal, L. Lucioni, C 2002). "Assessing the impact of complications on the cost of Type II diabetes." In The Cost of Diabetes Type II in Europe. The CODE-2 Study. Diabetologia, 45, S13 S17.
58. World Health Organization and International Diabetes Federation Europe 1990). Diabetes care and Research in Europe: The Saint Vincent Declaration. Diabetic Medicine, 7, 360.
59. Zebrack, J. S. Anderson, J. L 2002). Role of inflammation in cardiovascular disease: How to use C-reactive protein in clinical practice. Progress in Cardiovascular Nursing, 17, 174 185.
60. Zimmet, P., Alberti, K. G. Shaw, J 2001). Global and societal implications of the diabetes epidemic. Nature, 414, 782 787.